Skip to main content
OpenTrials
Completed

NCT Number: NCT04949906

Study on Yangxue Nao Granules Reducing the Risk of Stroke

Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the real world

Completed

Looking for future studies?

Notify Me

Key information

About this study

Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the real world Study Design. This study was a single center real world study. Through the review data, this study included in January 1, 2017 to September 30, 2019, see a doctor at Peking University third hospital neurology, emergency diagnosis of acute ischemic stroke, and venous thrombolysis in patients with a queue, on the basis of whether the application have serum brain particles are divided into a group and the control group, serum application parameters and nonparametric comparison, K-M curve and Cox regression model were used to evaluate the effectiveness of Yangxuenao granules in reducing bleeding conversion after intravenous thrombolysis by comparing the number of microbleeding, stroke severity score and modified Rankin score after 3 months follow-up with the weighted craniocerebral magnetic sensitivity imaging sequence reexamined within 48 hours.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A cohort of patients admitted to the Department of Emergency Neurology at Peking University Third Hospital on January 1, 2017 and admitted on September 30, 2019, who were diagnosed with acute ischemic stroke and underwent intravenous thrombolysis.

Exclusion criteria

  • Patients who underwent intravenous thrombolysis but were confirmed to be apoplexy
  • like by imaging and other clinical examinations; Incomplete craniocerebral MRI examination;
  • Bridging endovascular therapy;
  • The previous application of Yangxuenao granules or other drugs with similar effects;

Treatment and study plan

Raise serum brain granules

Drug

Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke

No nourishing serum brain granules are used

Drug

No nourishing serum brain granules are used

Primary outcomes

  1. Microhemorrhage (CMB) of T2* sequence in MRI after thrombolysis

    Time frame: 1 day

    The number of CMB is an important imaging marker reflecting microvascular injury.

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Official study title

A Real World Study of Yangxuenao Granules Reducing Bleeding Risk in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jul 2, 2021
Registry last updated
Jul 6, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.